Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B4TX
|
|||
Drug Name |
PMID28394193-Compound-47
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
PFIZER INC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H21Cl2N3O4
|
|||
Canonical SMILES |
CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C4=C(ON=C4C)C)Cl)OC
|
|||
InChI |
1S/C22H21Cl2N3O4/c1-10-7-17(30-4)15(21(28)25-10)9-27-6-5-13-16(23)8-14(20(24)19(13)22(27)29)18-11(2)26-31-12(18)3/h7-8H,5-6,9H2,1-4H3,(H,25,28)
|
|||
InChIKey |
HCXPMZKLLCLZQX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
KEGG Pathway | MicroRNAs in cancer | |||
NetPath Pathway | IL2 Signaling Pathway | |||
Reactome | PRC2 methylates histones and DNA | |||
Oxidative Stress Induced Senescence | ||||
PKMTs methylate histone lysines | ||||
WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
Endoderm Differentiation | ||||
Integrated Pancreatic Cancer Pathway | ||||
Histone Modifications | ||||
Cell Differentiation - meta | ||||
miRs in Muscle Cell Differentiation | ||||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.